Acrux Limited (ASX:ACR)

Market Cap	5.73M
Revenue (ttm)	1.19M
Net Income (ttm)	-5.95M
Shares Out	409.26M
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	2.33
Dividend	n/a
Ex-Dividend Date	n/a

Volume	132,099
Average Volume	383,923
Open	0.0140
Previous Close	0.0140
Day's Range	0.0140 - 0.0140
52-Week Range	0.0120 - 0.0580
Beta	0.81
RSI	44.70
Earnings Date	Aug 26, 2025

About Acrux

Acrux Limited, together with its subsidiaries, develops and commercializes generic and topically applied pharmaceutical products in Australia, Europe, the United States, and internationally. The company provides estradiol transdermal sprays to women for the treatment of flushes associated with menopause under the Evamist and Lenzetto brand names; Dapsone 5% and Dapsone 7.5%, which are gels for the treatment of acne vulgaris; and Lidocaine and Prilocaine Cream USP, a topical anesthetic cream. It is also involved in the development of Efinaconazo...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 43
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: ACR

Financial Performance

In 2025, Acrux's revenue was 1.19 million, a decrease of -76.63% compared to the previous year's 5.09 million. Losses were -5.95 million, 2.50% more than in 2024.